

Journal Pre-proof



Development and primary characterization of a human thyroid organoid *in vitro* model for thyroid metabolism investigation

Sofia Cristiani, Andrea Bertolini, Vittoria Carnicelli, Lucia Contu, Valentina Vitelli, Alessandro Saba, Federica Saponaro, Grazia Chiellini, Antonietta Raffaella Maria Sabbatini, Maria Anita Giambelluca, Paola Lenzi, Francesco Fornai, Leonardo Rossi, Gabriele Materazzi, Carlo Enrico Ambrosini, Grazia Rutigliano, Riccardo Zucchi, Ranieri Bizzarri, Sandra Ghelardoni

PII: S0303-7207(24)00233-8

DOI: <https://doi.org/10.1016/j.mce.2024.112377>

Reference: MCE 112377

To appear in: *Molecular and Cellular Endocrinology*

Received Date: 10 June 2024

Revised Date: 20 August 2024


Accepted Date: 23 September 2024

Please cite this article as: Cristiani, S., Bertolini, A., Carnicelli, V., Contu, L., Vitelli, V., Saba, A., Saponaro, F., Chiellini, G., Sabbatini, A.R.M., Giambelluca, M.A., Lenzi, P., Fornai, F., Rossi, L., Materazzi, G., Ambrosini, C.E., Rutigliano, G., Zucchi, R., Bizzarri, R., Ghelardoni, S., Development and primary characterization of a human thyroid organoid *in vitro* model for thyroid metabolism investigation, *Molecular and Cellular Endocrinology*, <https://doi.org/10.1016/j.mce.2024.112377>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2024 Published by Elsevier B.V.

Graphical Abstract



1 Development and primary characterization of a human thyroid 2 organoid *in vitro* model for thyroid metabolism investigation

3 *Sofia Cristiani*^{1†}, *Andrea Bertolini*^{1†}, *Vittoria Carnicelli*¹, *Lucia Contu*¹, *Valentina Vitelli*¹,
4 *Alessandro Saba*¹, *Federica Saponaro*¹, *Grazia Chiellini*¹, *Antonietta Raffaella Maria*
5 *Sabbatini*¹, *Maria Anita Giambelluca*², *Paola Lenzi*², *Francesco Fornai*^{2,3}, *Leonardo Rossi*⁴,
6 *Gabriele Materazzi*⁴, *Carlo Enrico Ambrosini*⁴, *Grazia Rutigliano*¹, *Riccardo Zucchi*¹, *Ranieri*
7 *Bizzarri*¹, *Sandra Ghelardoni*^{1*}

8 ¹ *Department of Surgical, Medical and Molecular Pathology and Critical Care Area, University of Pisa, via Roma*
9 *55, 56126 Pisa, Italy.*

10 ² *Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, via*
11 *Roma 55, 56126 Pisa, Italy.*

12 ³ *Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Neuromed, 86077 Pozzili, Italy*

13 ⁴ *Endocrine Surgery Unit, University Hospital of Pisa, Pisa, Italy*

14 ** Corresponding author, Department of Surgical, Medical and Molecular Pathology and Critical Care Area,*
15 *University of Pisa, via Roma 55, 56126 Pisa, Italy, sandra.ghelardoni@unipi.it*

16

17 † *The authors contributed equally to this manuscript*

18

19 Abstract

20 A 3D thyroid model was developed to address the limitations of 2D cultures and study the
21 effects of compounds like 3-MNT on dehalogenase 1 (IYD) and metabolic activity.
22 Morphology was assessed by TEM, and the expression of tissue-specific genes (*TPO*, *TSHR*,
23 *PAX8*, *TTF-1*, *NIS*, *IYD*, *TG*) and metabolic features were analyzed using qRT-PCR,
24 immunofluorescence, western blotting, ELISA, and LC-MS/MS, with and without TSH
25 stimulus and 3-MNT treatment. Confocal and TEM analyses confirmed a follicle-like 3D
26 structure. Expression of *TPO*, *NIS*, *TG*, *TSH*, and *PAX* markers was significantly higher ($p <$
27 0.05) in 3D versus 2D cultures, and ELISA showed increased TG protein production. 3-MNT
28 treatment inhibited IYD activity, indicated by increased MIT and DIT in the media, and
29 significantly altered ($p < 0.05$) *NIS*, *TG*, *IYD*, *TSHR*, and *TPO* expression. These findings
30 suggest 3D thyroid cultures closely replicate tissue traits and functionality, providing a valuable
31 tool for thyroid research.

32 **Keywords:** thyroid; organoid; TSH; IYD; 3-MNT; disruptors.

33

34

35

36

37

38 1. Introduction

39 The thyroid gland regulates metabolism by producing thyroid hormones (TH), mainly T4
40 (Thyroxine) and T3 (Triiodothyronine) (Gereben et al., 2015; Luongo et al., 2019). T4 acts as
41 a prohormone, converting into active T3 in peripheral tissues via deiodinase enzyme (DIOs)
42 (Bianco and Kim, 2006). The Hypothalamic-Pituitary-Thyroid axis (HPT) maintains TH
43 levels. Thyrotropin-Releasing Factor (TRH) stimulates pituitary Thyroid Stimulating hormone
44 (TSH) release, which triggers TH synthesis (Estrada et al., 2014; Fekete and Lechan, 2014)
45 within thyroid follicles. Here, thyroglobulin (TG), containing tyrosine residues, facilitates
46 iodine attachment (Citterio et al., 2019). The sodium-iodide symporter (NIS) enables iodine
47 uptake into thyroid cells (Wright and Turk, 2004). TSH regulates TG endocytosis via the TSH
48 receptor (TSHR) and iodide efflux through channels like pendrin (Gillam et al., 2004; Kogai
49 et al., 1997; Ohno et al., 1999; Portulano et al., 2014). Thyroid peroxidase (TPO) catalyzes
50 iodination and coupling of iodotyrosines, MIT and DIT, on TG to synthesize TH. The coupling
51 MIT and DIT leads to the formation of T4 and T3 (Ameziane-El-Hassani et al., 2005; Belforte
52 et al., 2015; Carvalho and Dupuy, 2013; Godlewska et al., 2014; Yokoyama and Taurog, 1988).
53 TSH stimulation leads to endocytosis of newly TH bound to TG into thyrocytes, where
54 lysosomal enzymes release T3 and T4. Uncoupled MIT and DIT are enzymatically deiodinated
55 by iodotyrosine dehalogenase (DEHAL1/IYD), enabling their reuse in TH biosynthesis
56 (Gnidehou et al., 2004). Transcription factors PAX8 (Paired Box-8) and TTF-1 (Thyroid
57 Transcription Factor-1) are responsible, together with all the aforementioned actors, for the
58 development and correct functioning of the thyroid gland (Fabbro et al., 1994).

59 *In vitro* models offer a platform for dissecting cellular pathways and responses, facilitating the
60 exploration of thyroid physiology and pathophysiology (Samimi et al., 2021). Conventional
61 two-dimensional (2D) cell culture systems have long served as fundamental tools for
62 understanding and investigating cellular and molecular biology, including thyroid metabolism.
63 Yet, their simplified nature often fails to recapitulate the physiological complexity observed *in*
64 *vivo*, where cells exist in a complex 3D microenvironment with organized interactions among
65 neighboring cells and the extracellular matrix (ECM), crucial for differentiation, proliferation,
66 and function. 2D cultures lack nutrients, oxygen gradients and structural complexity of the
67 tissue, resulting in altered cell morphology and function, and forming unnatural monolayers
68 that affect signaling pathways, gene expression, and behavior. Furthermore, 2D cultures do not
69 replicate the mechanical forces experienced by cells *in vivo*, such as tension, compression, and
70 shear forces, resulting in differences in cell signaling and physiology. The advent of three-
71 dimensional (3D) organoid models has revolutionized the field by providing a more
72 physiologically relevant environment that better recapitulates tissue architecture and function
73 (Samimi et al., 2021). First studies on thyroid organoids were carried out by differentiating
74 mouse embryonic or pluripotent stem cells into thyroid follicular cells *in vitro*, generating
75 functional thyroid tissue (Antonica et al., 2012; Kurmann et al., 2015; Longmire et al., 2012;
76 Shankaran et al., 2021) till the use of human embryonic stem cell or primary thyrocytes
77 (Deisenroth et al., 2020; Romitti et al., 2022; Wang et al., 2016). The transition from 2D to 3D
78 culture systems represents a paradigm shift, offering researchers a more accurate representation
79 of *in vivo* conditions and enhancing the translational potential of *in vitro* findings (Lelièvre et
80 al., 2017). Organoids, self-organizing 3D structures derived from stem cells or tissue

81 progenitors, have gained prominence as valuable tools in various fields of biomedical research
82 (Edmondson et al., 2014). Their ability to mimic organ-specific architecture and function
83 makes them particularly suitable for studying complex biological mechanisms, including
84 endocrine function (Dalir Abdolahinia and Han, 2023; Hwang et al., 2021; Jubelin et al., 2022).
85 The utilization of organoids in *in vitro* assays presents unprecedented opportunities for
86 investigating thyroid metabolism with enhanced fidelity and relevance. Moreover, this
87 approach aligns with the scientific 3R principles (Replacement, Reduction, Refinement),
88 promoting ethical use of different biological matrices in research, maximizing the possible
89 scientific outcomes, advancing our understanding of thyroid physiology in a more humane and
90 efficient manner (Tannenbaum and Bennett, 2015). Thyroid alterations may occur during
91 physiological processes such as pregnancy as well as specific disorders including tumor
92 malignancy. Very often thyroid dysfunctions are triggered by exogenous disruptors, which
93 interfere with the regular production of hormones, also known as endocrine disruptors (EDs).
94 The rise in endocrine disorders and the widespread presence of endocrine-disrupting chemicals
95 highlight the need for robust models to assess their impact on thyroid function. Exposure to
96 EDs has been linked to an increase in neurodevelopmental disorders and a decline in average
97 IQ (Asawasinsopon et al., 2006; Chevrier et al., 2008; de Escobar et al., 2007; Haddow et al.,
98 1999; Hetzel, 2000; Lopez-Espinosa et al., 2009; Román et al., 2013; Zimmermann et al.,
99 2008). Some EDs may inhibit IYD, leading to iodine loss in urine, mimicking iodine
100 deficiency, and alter the cellular redox and metabolic state (González-Guerrero et al., 2023;
101 Shareef et al., 2023). Organoids offer a promising approach to understanding endocrine
102 disruption mechanisms, assessing health risks from environmental contaminants, and guiding
103 regulatory efforts to protect public health. Given that a significant part of worldwide population
104 will experience a thyroid disorder during their lifetime (Sewell and Lin, 2014), the need to
105 develop thyroid organoid models for finding appropriate and specific treatments becomes even
106 more critical.

107 In this study, we focused on the development and primary characterization of a human thyroid
108 organoid *in vitro* model tailored with the aim of evaluating a 3D model for investigating thyroid
109 metabolism and observing the effects of compounds which can interfere in recycling iodine.
110 Morphology was characterized by confocal and transmission electron microscopy (TEM). The
111 expression of functional thyroid markers and metabolic features, with and without TSH
112 stimulus or upon treatment with 3-mono-L-nitro tyrosine (3-MNT), a competitive inhibitor of
113 IYD, were examined by quantitative reverse transcription real time polymerase chain reaction
114 (qRT-PCR), immunocytofluorescent staining, western blotting and ELISA. MIT/DIT release
115 upon 3-MNT treatment as well as TH production were monitored using tandem mass
116 spectrometry coupled to high performance liquid chromatography (LC-MS/MS).

117

118 **2. Materials and methods**

119

120 *2.1 Chemicals*

121 Unless otherwise specified, all reagents were from Sigma Aldrich-Merck (Merck KGaA,
122 Darmstadt, Germany). Reagents for 2D or 3D cell cultures were from Gibco™, Thermo

123 Scientific™, Waltham, MA, USA. Solvents for HPLC-MS/MS measurements were HPLC
124 grade, and the other chemicals were reagent grade. ¹³C₉-MIT and ¹³C₉-DIT were kindly
125 provided by Prof. Alireza Mani (University College of London, UK), since they were not
126 commercially available.

127

128 *2.2 2D cell culture and 3D organoid formation*

129 Non-tumorous thyroid samples were obtained from healthy donors (University Hospital of
130 Pisa, Italy) during routine thyroidectomy procedures in individuals at Endocrine Surgery Unit.
131 All participants signed the informed consent and advance directives (according to Law No.
132 219/2017). To allow cell isolation, the samples were minced and digested through collagenase
133 IV (1 mg/mL and 3 mM CaCl₂) at 37 °C and 5% CO₂ for 2 hours. The isolated cells were
134 seeded into flasks with Humanized 7 homeostatic additives (h7H) medium (Bravo et al., 2013)
135 supplemented with standard 5% Newborn Calf Serum (NCS), 5% Fetal Bovine Serum (FBS),
136 and 2% Penicillin-Streptomycin, and incubated at 37 °C and 5% CO₂ in a humidified chamber,
137 until 70- 80 % of confluence was reached. Then, confluent primary thyrocytes were detached
138 (passage 0) with TrypLE™ Express Enzyme, no phenol red and plated in round-bottomed
139 Nunclon Sphera™ 96-well Microplates in h7H and 3% Geltrex™, 37 °C and 5% CO₂, at a
140 density of 10000 cells/well to maintain uniform size among cell aggregates that were collected
141 after 8 to 12 days from seeding, without further passages. All experiments utilized cells at
142 passage 0 (P0) or 1 (P1) for 2D, unless otherwise indicated.

143

144 *2.2 3D Organoid treatment*

145 On day 8, the following treatments were performed for 4 days on organoids: no TSH (control),
146 and TSH (2 mU/mL, from bovine pituitary); 0.01 μM 3-MNT, 1 μM 3-MNT, 100 μM 3-MNT,
147 or vehicle (0.05 mM NaOH), all in TSH condition. At the end of each treatment, organoids
148 were collected for morphological and functional characterization experiments as depicted in
149 the following paragraphs. The experiment was repeated on three donors.

150

151 *2.3 Human Thyroglobulin (TG) Enzyme-linked immunosorbent assay (ELISA)*

152 Human Thyroglobulin ELISA (Human Thyroglobulin ELISA kit #EHTG Thermo
153 Scientific™) was performed following the manufacturer's protocol in the cell culture effluent.
154 Analysis was conducted on exhausted h7H medium collected from both 2D and 3D cultures
155 derived from a single donor, after 4 days of incubation with or without 3-MNT or vehicle. Data
156 collection was conducted on a microplate reader at 450 nm (Bio-Rad, Hercules, CA, USA).

157

158 *2.4 Immunofluorescence assay*

159 Both 2D and 3D thyroid cultures were fixed in 4% Paraformaldehyde (PFA) in PBS for 30
160 minutes at room temperature (RT). Organoids were maintained in suspension, rinsed three

161 times in 0.1% TBST wash buffer and permeabilized with 0.5% TBST buffer for 30 minutes.
162 After a wash with 0.1% TBST, organoids were incubated in blocking buffer (0.1% TBST plus
163 2% w/v BSA) for 1 hour at RT and, thus, incubated with the primary antibody (Table S1)
164 overnight at 4 °C, and then with the corresponding secondary antibody (Table S2). Organoids
165 were mounted on microscope slides with DAPI Mounting Medium (Abcam). Images were
166 acquired using a laser scanning confocal microscope (Nikon, Eclipse, Ti) (Amstelveen,
167 Netherlands)) and processed using ImageJ Programme (Sun-Java, National Institutes of Health,
168 USA). For 2D culture immunolabelling, cells were permeabilized with 0.1% Triton X-100 in
169 PBS for 20 minutes, then incubated with the blocking solution (2% BSA) for 45 minutes at RT.
170 2D systems were incubated with the same primary antibodies used for the 3D cultures, except
171 for α -tubulin (Table S1) primary antibody which replaced Phalloidin antibody to amplify the
172 signal by indirect immunolabelling and then with the corresponding secondary antibodies
173 (Alexa Fluor™ 488, 1:400, goat anti-mouse ab150113, Abcam, used against mouse α -tubulin
174 primary antibody).

175

176 2.5 Gene expression

177 For gene expression comparison of 2D and 3D cultures total RNA was isolated from 1.8×10^6
178 cells at passages P0 and P1 and from 16 pooled organoids collected within 12 days from
179 seeding. RNA extraction was performed with Direct Zol RNA Microprep Kit (Zymo Research,
180 USA), following company protocol. The kit on-column DNase incubation step was included.
181 RNA was quantified with Qubit Fluorometer (Thermo Fisher Scientific) in association with
182 Quanti It RNA BR Kit (Thermo Fisher Scientific). Total RNA (100 to 500 ng) was
183 retrotranscribed into cDNA by using iScript gDNA Clear cDNA Synthesis Kit (Bio-Rad) as
184 manual protocol indications.

185 Relative quantity of gene transcripts was measured by RT-PCR on cDNA samples using
186 SsoAdvanced Universal SybrGreen Master Mix (BioRad) on a CFX Connect RT-PCR
187 Detection System (Bio-Rad). All reactions were conducted in duplicate. Negative control of
188 retro-transcription was performed to exclude any interference from residual genomic DNA
189 contamination. PCR Primer Assay (Bio-Rad) for thyroid markers genes were indicated in
190 supplementary materials, Table 1. Samples were analyzed by the $2^{-\Delta\Delta C_t}$ method as described
191 by Livak and Schmittgen (Livak and Schmittgen, 2001). The relative expression of the target
192 genes was normalized to the level of *GAPDH*.

193

194 2.6 TEM evaluation

195 For TEM analysis, human thyroid organoids were rinsed in PBS, and fixed in a solution of
196 2.0% paraformaldehyde and 0.1% glutaraldehyde in 0.1 M PBS (pH 7.4) for 90 minutes at 4
197 °C. After washing in PBS 0.1 M, samples were post-fixed in 1% osmium tetroxide (OsO₄,
198 Agar Scientific Ltd, Stansted, Essex) for 1 hour at 4 °C. Samples were then dehydrated in
199 increasing ethanol solutions (50%, 70%, 90% and 95% for 5 minutes; and 100% for 60
200 minutes), and finally, they were embedded in Epoxy resin. Semi-thin slices (about 1 μ m thick)
201 were cut by ultramicrotome (Leica Microsystems, Leica Microsystems, Wetzlar, Germany),

202 and they were stained with toluidine blue and observed at light microscopy (Nikon, Tokyo,
203 Japan). Semi-thin slices served as a guide to cut specific ultra-thin slices (70–90 nm thick) to
204 combine light and electron microscopy analysis of specific micro-areas. Ultra-thin slices were
205 counterstained with uranyl acetate and lead citrate and were observed at Jeol JEM SX100
206 electron-microscope (Jeol, Tokyo, Japan).

207

208 *2.7 Protein expression analysis*

209 To observe the presence of IYD protein in the different cell cultures, qualitative IYD expression
210 analysis was assessed in 2D thyroid cell cultures and organoids (thyroid tissue extracts were
211 used as positive controls), which were collected after 8 days from seeding. Cells or pools of 32
212 organoids were extracted in ice-cold extraction buffer as elsewhere described (Bandini et al.,
213 2022). Thyroid samples were homogenized using a Teflon-glass homogenizer in ice-cold
214 buffer for tissue extraction (Tissue extraction reagent, Thermo-Fischer Scientific,
215 supplemented with 1 mM phenylmethanesulfonyl fluoride and protease inhibitor cocktail) and
216 then centrifuged to collect supernatant. Protein concentration was determined by Protein Assay
217 Dye Reagent Concentrate (Biorad). To perform western blotting, proteins were resolved by
218 SDS-PAGE (4–20% acrylamide separating gel, Biorad) and transferred onto a PVDF
219 membrane (Biorad), which was incubated with primary antibody (Table S4) and then with anti-
220 rabbit secondary antibody (Table S4). For neutralization, antibody for IYD was incubated
221 overnight at 4 °C with excess of blocking peptide (Table S4). Immunoblots were visualized by
222 means of a chemiluminescence reaction by ImageLabTM Software under a luminescent image
223 analyzer (Chemidoc XSR+, Bio-Rad)

224

225 *2.8 Measurement of cell viability*

226 The cytotoxic effect of 3-MNT on primary thyrocytes was determined using a 3-(4,5-
227 Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, according to
228 manufacturer's specifications. MTT assay was performed on cells treated with increasing
229 concentrations of 3-MNT, from 0.05 μ M up to 200 μ M, or an equal volume of 0.05 mM NaOH
230 as control for 24 hours. Absorbance was measured at 570 nm on a microplate
231 spectrophotometer (Bio-Rad). Afterwards three concentrations of this IYD inhibitor were
232 chosen for 3-MNT treatment experiments.

233

234 *2.9 LC-MS/MS Media sample analysis*

235 Each condition (inhibitor 3-MNT 0.01 μ M, 1 μ M and 100 μ M, and the vehicle 0.05 mM NaOH;
236 TSH 2 mU/mL and no further addition of TSH) was performed on 16 different organoids
237 (therefore 16 media wells), and the media from each of the 16 wells were collected for analysis.
238 To minimize variability in the evaluation of tyrosines and thyronines concentrations within the
239 various wells, media pools were created by taking the same volume (6.25 μ L) from each well
240 (for each treatment) to reach a final volume of 100 μ L. To appreciate tyrosines and thyronines
241 production differences in organoids culture media, with and without a TSH stimulus to study
242 the active organoid metabolism (2 mU/mL for 4 days), media were collected and analyzed for
243 T3, T4, MIT and DIT concentrations as well.

244 To each 100 μ L of media sample or pool, 10 μ L of a 100 ng/mL mixture of labelled internal
245 standards, containing $^{13}\text{C}_9$ -MIT, $^{13}\text{C}_9$ -DIT, $^{13}\text{C}_6$ -T3 and $^{13}\text{C}_6$ -T4 were added. The samples were
246 then processed and analyzed as previously described (Borsò et al., 2022; González-Guerrero et
247 al., 2023; Shareef et al., 2023). Since the method was originally optimized on plasma/serum
248 and urines (Borsò et al., 2022; González-Guerrero et al., 2023; Shareef et al., 2023), the
249 recovery rates (%) of analytes and the matrix effect in the media analyzed samples were
250 calculated as reported by Matuszewski et al. 2003 (Matuszewski et al., 2003). Recovery was
251 evaluated by comparing the peak areas of isotope labelled internal standards analytes-
252 analogues added to the media before and after the extraction procedure, while the estimation
253 of matrix effect was performed comparing the peak areas of the isotope labelled internal
254 standards analytes-analogues added to water (A) and media (B) previously subjected to the
255 extraction process $[(B/A) \times 100]$.

256

257 *2.10 Statistical Analysis*

258 Results are expressed as the mean \pm S.E.M. Differences between two groups were analyzed by
259 Student's t-test, while differences between multiple groups were analyzed by one-way or two-
260 way ANOVA as detailed for each figure. In the experiments aimed at determining differences
261 between groups, Tukey's post hoc comparison test was applied. The threshold of statistical
262 significance was set at $P < 0.05$. GraphPad Prism version 9.0 for Windows (GraphPad
263 Software, San Diego, CA, USA) was used for data processing and statistical analysis.

264

265

266 **3. Results**

267 *3.1 Thyroid 3D culture formation*

268 Organoids derived from human non-tumorous primary thyrocytes were collected after 8 to 12
269 days following cell seeding. In Figure 1.A it is possible to see the formation and spatial
270 organization processes of the 3D cultures from confluent primary thyrocyte seeding up (Figure
271 1.A1-2) to the collection of organoids (Figure 1.A 3-5). Each well of the 96-well microplates
272 hosted just a single organoid whose diameter was about 200 μ m. No numerous smaller
273 organoids with variable diameters were found in the same well. The spheroidal morphology
274 and 200 μ m diameter were two features preserved among organoids formed in different wells
275 within the same experimental microplate.

276

277 *3.2 Immunofluorescence characterization*

278 The morphology and positivity for thyroid markers of both 2D and 3D culture systems were
279 investigated by immunofluorescent staining and laser scanning confocal microscopy (LSCM)
280 visualization. As shown in Figure 1.B, monolayer P0 primary thyrocytes preserved the identity
281 of the original organ by expressing functional thyroid marker IYD, TSHR and TTF-1.
282 However, the polarized structure typical of follicular cells, defined by a basolateral membrane
283 and an apical membrane displaying microvilli (Arvan et al., 1997), started to be less visible
284 due to progressive reduction in thyrocyte phenotype induced by the monolayer culture

285 condition. Similarly, the 3D cultures (Figure 1, C) proved to maintain positive labelling for the
286 same functional thyroid markers, IYD, TSHR and TTF-1. To provide a deeper investigation
287 of 3D culture structure, we proceeded with a morphological characterization by TEM
288 microscopy.

289

290 3.3 TEM morphological characterization

291 To analyse the morphology of human thyroid organoids we used light microscopy on semi-
292 thin slices stained with toluidine blue and transmission electron microscopy. This approach
293 allows a progressive increase in magnification in order to detail the architecture of the samples.
294 Toluidine blue staining of resin embedded semi-thin sections provides high quality and clear
295 detailed images of structures as reported in representative Figure 2A. The thyroid organoid
296 shows a central cavity delimited by epithelial cells. The central cavity is well evident in
297 ultrathin sections (Figure 2.A1-A2). The cell apical surface, that protrudes in the cavity,
298 possesses short and sparse microvilli (Figure 2.A3). Droplets, containing a poorly electron dense
299 material similar to the colloid, are located in sub-apical cytoplasm (Figure 2.A4).

300 Figure 2.B1 shows two adjacent cells with junctional complexes at their apical lateral
301 membrane. Epithelial cells possess well developed Golgi apparatus and rough endoplasmic
302 reticulum (RER), in particular RER is located in the nuclear region and its cisternae are
303 markedly dilated (Figure 2.B2-B3). Several mitochondria are dispersed in the cytoplasm
304 (Figure 2.B2-B4). Lysosomes are large in diameter, and they appear in different forms (Figure
305 2.B4). Moreover, basal body of primary cilium (PC) was observed in epithelial cells (Figure
306 2.B1).

307

308 3.4 Expression of functional markers in thyrocyte preparations

309 3.4.1 Genetic analysis

310 We evaluated the expression of thyroid differentiation markers genes *PAX8* and *NKX2-1/TTF-*
311 *1* and four thyroid functional marker genes (*IYD*, *TG*, *TSHR*, *TPO*, *NIS*) from both monolayer
312 and 3D cultures. As reported in Figure 3.A, the relative expression of each gene was
313 significantly higher in the 3D system than in the two 2D systems. Particularly, the expressions
314 of *IYD* (fold-change: 24.15; *** $p < 0.001$), *TG* (fold change: 3.55; * $p < 0.05$), *TSHR* (fold
315 change: 6.13; ** $p < 0.01$), *TPO* (fold change: 9.52; * $p < 0.05$), *NIS* (fold change: 179.72;
316 * $p < 0.05$) and transcription factor *PAX8* (fold change: 216.52; ** $p < 0.01$) and *TTF-1* (fold
317 change: 9.93; * $p < 0.05$) genes were significantly increased in the organoid models, supporting
318 the preservation of thyroid differentiation identity and functionality in organoids. These results
319 indicate that the transcriptional regulation of thyrocyte differentiation marker genes is
320 remarkably influenced by the organoid format which maintains and promotes a differentiated
321 thyroid phenotype.

322

323 3.4.2 Western Blotting analysis

324 As shown in Figure 3.B (B1-B2), 2D cell lysates or tissue extracts, the latter used as positive
325 control (C+), incubated with the anti IYD antibody, showed several bands but only the

326 appearance of band between 25 and 37 kDa was prevented by peptide neutralization. In 2D cell
327 lysates (Figure 3.B1), IYD was detected only at seeding passage (P0) but not at the subsequent
328 passages, corroborating the loss of phenotype characterization observed by
329 immunofluorescence analysis as described above. IYD protein expression was also detectable
330 in organoids cultured in Nunclon plates for 8-12 days, (Figure 3.B4), indicating a continuous
331 production of the enzyme in the 3D system opposed to the 2D system. To verify the presence
332 of proteins in extracts, the same blots were stripped and then probed with α -actin (Figure 3. B3
333 and B5, for B1 and B4 respectively).

334

335 3.4.3 TG production analysis by ELISA assay

336 Monitoring TG concentration in 2D, namely at P0 and P1 passages, and 3D models is a useful
337 tool to evaluate if TH biosynthesis activity is preserved. As depicted in Figure 3.C, the 3D
338 system produced a significantly greater amount (TG: 2066 ± 57 ng/mL, **** $p < 0.0001$) of
339 thyroglobulin than the 2D monolayer (TG: P0, 809 ± 122 ng/mL; P1, 978 ± 72 ng/mL), in
340 normal h7H medium culture condition, revealing how significantly relevant 3D spatial
341 organization could be for primary thyrocytes to maintain the production of TH precursor.

342

343

344 3.5 Effects of TSH stimulus on thyroid-like follicle metabolism

345

346 3.5.1 TG production

347 To qualitatively evaluate the responsiveness to TSH stimulation on the production of TG,
348 which is physiologically regulated by the HPT axis, 3D cultures were incubated with or without
349 2 mU/mL TSH for 4 days after seeding (from day 8 to day 12) and TG concentration was
350 assessed in culture medium. As shown in Figure 4.A, if compared to the no TSH condition
351 (362 ± 51 ng/mL), TSH treatment led to a slight increase in TG (422 ± 75 ng/mL), although
352 not statistically significant.

353

354 3.5.2 Gene expression analysis

355 We investigated the effect of adding an extra amount of TSH hormone (2 mU/mL) to h7H
356 medium for 4 days on TH biosynthesis gene expression, as opposed to TSH starvation, which
357 consisted in no further addition of the hormone to the media. Despite an overall increase in *IYD*
358 (fold-change: 2.40), *TG* (fold-change: 2.31), *TSHR* (fold-change: 1.79) and *TPO* (fold-change:
359 2.02) gene expression levels (Figure 4.B), we found no significant difference between the two
360 experimental conditions, potentially due to the already presence of TSH in the h7H medium
361 composition as well as the 4-day limited time period of the hormone addition.

362

363 3.5.3 LC-MS/MS media analysis for organoid TH production

364 The organoid production of TH in the media, under a TSH stimulus, was evaluated by assessing
365 their concentration using a previously validated LC-MS/MS analytical method, specifically
366 adapted for our aim. Since the method was initially optimized for plasma and urine matrix, the
367 recovery rates (%) of analytes and the matrix effect in the media analyzed samples were
368 calculated. All analytes displayed a recovery rate ranging from 60% to 90%, while matrix effect
369 was in the range of 64- 99% therefore confirming the validity of the analytical method for these
370 types of matrix as well. The production of TH by organoids is depicted in Figure 4.C as ratio
371 between the concentration of TH in the media recovered from the organoid wells after 4 days
372 of treatment with an additional TSH external stimulus and TH in the blank media, without
373 additional TSH stimulus. TSH stimulation did not significantly trigger changes in either T3 or
374 T4 concentration (1.149 ± 0.149 and 1.109 ± 0.109 for T3 and T4 respectively, $P=NS$). This
375 could be due to the endogenous quantities of TH in the blank media, the basal TSH stimulus
376 given from the h7H formulation and the presence of a single organoid in each well in our
377 experimental settings.

378

379 *3.6 Assessment of 3-MNT treatment of 3D culture*

380

381 *3.6.1 MTT assay to determine cell viability with 3-MNT incubation*

382 To screen the concentrations of IYD competitive inhibitor 3-MNT compatible with cell
383 viability, we performed MTT assay on monolayer primary thyrocytes. Figure 5.A shows that
384 no significant difference of viability was found among the tested concentrations. Therefore, we
385 decided to use three concentrations within the range tested: 0.01 μ M, 1 μ M, 100 μ M. This
386 choice was also supported by the concentrations of 3- MNT previously reported in literature
387 (Olker et al., 2021, 2018).

388

389 *3.6.2 LC-MS/MS media analysis for organoid 3-MNT inhibition of IYD function*

390 To evaluate the interfering action of the inhibitor 3-MNT on the deiodination activity of
391 DEHAL1, we assessed changes in concentrations of MIT and DIT within the culture medium
392 of the organoids upon increasing doses of 3-MNT. Even in these cases, to account for
393 endogenous amounts of TH and precursors in the media and to minimize biological variability
394 effects, we expressed differences between groups as ratios between the treated groups (NaOH
395 + 0.01 - 1 -100 μ M 3-MNT) and control vehicle condition (NaOH). As shown in Figure 5.B,
396 adding the inhibitor to the organoid culture medium resulted in an increasing presence of MIT
397 and DIT in the media, correlated with inhibitor concentration. There was a significant
398 difference between the control group and the 100 μ M treatment ($p < 0.0001$ for MIT and $p <$
399 0.05 for DIT), confirming that 3-MNT inhibits IYD's recycling of iodine from TH precursors.
400 However, T3 and T4 levels remained unaffected by 3-MNT. This analysis demonstrates that
401 3-MNT can inhibit the enzyme IYD, preliminarily candidating our model as feasible for
402 studying the interference of IYD caused by some types of EDs.

403

404 3.6.3 Thyroglobulin production analysis by ELISA assay after 3-MNT treatment

405 Based on evidence from our LC-MS/MS analysis results, organoids were treated with 100 μ M
406 3-MNT for 4 days to shed light on the effect of IYD competitive inhibitor on TH biosynthesis.
407 The resulting data, depicted in Figure 5.C, indicate that the 3-MNT infusion caused a
408 significant 1.4 -fold increase in the production of TG, compared to the control condition (460
409 \pm 16 ng/mL vs 321 \pm 33 ng/mL, **p < 0.01). This was in line with the LC-MS/MS analysis
410 data, where IYD inhibition by 3-MNT caused a disruption of iodine recycling mechanism,
411 leading to an increase in the substrates of IYD, MIT and DIT (Figure 5.B) and the activation
412 of a feedback loop mechanism leading to an upstream TG increase (Alikhani et al, 2023).

413

414 3.6.4 Gene expression analysis for organoid 3-MNT inhibition of IYD function

415 To investigate the effect of 3-MNT on the transcription of TH biosynthesis genes in 3D
416 cultures, we evaluated the gene expression of *IYD*, *TG*, *TSHR*, *NIS* and *TPO*, by qRT-PCR
417 assay, after 4-day incubation with the above-mentioned treatment as well. As reported in Figure
418 5.D, the expression of *TSHR* (fold-change: 0.10, ***p < 0.001), *NIS* (fold-change: 0.50; *p
419 <0.05) and *TPO* (fold-change: 0.40; ***p < 0.001) was significantly lower if compared to the
420 control, whereas *IYD* (fold-change: 3.12; **p < 0.01) and *TG* (fold-change: 2.31 ;*p < 0.05)
421 transcription levels were significantly higher than control condition (vehicle). These results are
422 in line with the LC-MS/MS and ELISA analysis described in the previous paragraphs: the
423 increased expression of *IYD* and *TG* could be considered a counteraction to its inhibition by 3-
424 MNT (Sun et al., 2015). Eventually, the reduction of *THRS*, *NIS* and *TPO* transcripts might be
425 related to the disruption of iodine recycling apparatus system.

426

427 4. Discussion

428 In this study, organoids derived from human non-tumorous primary thyrocytes were collected
429 8 to 12 days after cell seeding, with each well hosting a single 200 μ m organoid. Both 2D and
430 3D cultures were examined, revealing that 2D cultures expressed thyroid markers but lost
431 phenotype over time, while 3D cultures maintained positiveness for the same markers and
432 preserved thyroid differentiation and functionality, as shown by higher gene expression levels.
433 TEM microscopy showed well-developed structures within organoids, with cells exhibiting
434 active metabolism and mimicking *in vivo* thyroid architecture. Gene expression analysis
435 indicated that 3D cultures better preserved the thyrocyte phenotype. Additionally, 3D cultures
436 produced more thyroglobulin, indicating preserved thyroid function. Treatment with 3-MNT
437 increased MIT and DIT levels, confirming disrupted iodine recycling, while T3 and T4 levels
438 remained unchanged. Further analysis showed that 3-MNT treatment altered TH synthesis gene
439 expression, suggesting a compensatory response to IYD inhibition. Therefore, this 3D system
440 could be considered a tool to investigate thyroid metabolism, disorders and physiology, as an
441 alternative to traditional and already available *in vitro* models.

442 Recent studies have demonstrated how different aspects and applications of organoid models
443 have been explored. Organoid-based model systems of thyroid have been developed to study
444 autoimmune disease and Graves' hyperthyroidism (van der Vaart et al., 2021), or to produce a
445 thyroid model from human embryonic stem cell to transplant into mice and rescue

446 hypothyroidism (Romitti et al., 2022). Consequently, thyroid organoids can serve either as
447 thyroid diseases' models or as potential healthy tissues for transplantation in regenerative
448 therapies (Liang et al., 2022; Zhang et al., 2023; Zhao et al., 2022), thus, exploring new
449 approaches beyond animal studies.

450 In this context, thyroid organoids derived from either tumorous or non-tumorous thyroid cell
451 lines are becoming the gold standard for 3D culture systems. However, 3D thyroid organoids,
452 especially those derived from primary thyrocytes, can display heterogeneity and complexity in
453 cellular composition and in morphogenesis; furthermore, they lack vascularization, which over
454 time leads to a progressive necrotic degeneration, rising from the inner layers of epithelial cells
455 (Zhao et al., 2022). Therefore, improving the currently available protocols and techniques to
456 obtain reproducible 3D thyroid culture systems is considered a crucial issue for the study of
457 thyroid physiology and cancer. Deisenroth and colleagues developed a thyroid microtissue
458 model to screen chemicals that can cause the production of endocrine disruption in humans
459 (Deisenroth et al., 2020). In the development of a 3D model, they observed that primary
460 thyrocytes could self-assemble into organoids with follicle-like structures and produce TH
461 precursors, thyroglobulin, as well as actual TH, T3 and T4. Starting from the achievements of
462 Deisenroth and colleagues' work, we proceeded to develop a novel human 3D thyroid *in vitro*
463 model from primary thyrocytes isolated from healthy donors. Morphological and functional
464 characterization revealed that the 3D cultures preserved a structural and transcriptional memory
465 of the organ physiology, if compared to the corresponding 2D systems. Confocal acquisitions
466 demonstrated that in 2D models the polarized morphology, which is typical of thyroid follicular
467 cells, was lost, despite the unaltered positivity for thyroid markers. On the other hand, 3D
468 models displayed not only positivity for thyroid markers, specifically IYD, TTF-1 and TSHR,
469 as it was provided by the confocal images, but also preservation of thyroid follicular
470 morphology, shown by TEM acquisition. In addition, by confocal as well as brightfield
471 microscopy, it was possible to highlight morphological uniformity in size (about 200 μm
472 diameter) among organoids formed in separate wells of the same 96-well microplates.
473 However, due to technical limitations, fluorescence microscopy did not allow us to explore the
474 inner organization of thyrocytes within the 3D culture. For these reasons, turning to TEM was
475 an inevitable step to reveal the presence of an inner cavity filled with a colloid-like material,
476 surrounded by cuboidal follicular cells, that show a morphological polarity, with microvilli at
477 the apical membrane. In particular, the presence of cell apical microvilli into follicular lumen
478 is related to reabsorption of colloid by phagocytosis (Fujita, 1975). At ultrastructural level,
479 apical microvilli are frequently seen in functional active follicular epithelial cells (Fujita,
480 1975). Moreover, electron microscopy results show profiles of well-developed RER and Golgi
481 apparatus, which are correlated to cellular activity. In particular, small vesicles arising from
482 Golgi apparatus are typical of protein-secreting cells. Remarkably, ultrastructural analysis
483 demonstrates the presence of a cilium within organoid cells, which witnesses the model
484 reliability. In fact, cilium is a key organelle in the adult thyroid gland of different mammals
485 (human, pig, guinea pig and rabbit) (Wheatley, 2018, 2010, 2005). It is hypothesized that PC
486 possess a sensory activity, linked to intracellular downstream signaling pathways, and it plays
487 a role in the synthesis of TH (Fernández-Santos et al., 2019). All these ultrastructural
488 characteristics observed within cell organoids are highly reminiscent of morphological feature
489 described within thyroid gland; as matter of the fact, they are comparable to those obtained
490 from normal human thyroid as reported by Shiloh et al., 1987 (Shiloh et al., 1987), where fresh
491 surgical human tissue is analyzed. Moreover, thyrocytes from our experimental conditions

492 exhibited primary cilium as observed in human primary thyrocytes (Fernández-Santos et al.,
493 2019; Utrilla et al., 2015), and ultrastructural features very similar to organoids reported by van
494 der Vaart et al., 2021 (van der Vaart et al., 2021).

495 Besides the maintenance of morphological features, 3D models proved to be able to express
496 functional thyroid markers as revealed also by protein expression of IYD after 8- 12 days of
497 incubation, while IYD was lost in 2D cultures after the second passage. Furthermore, organoids
498 were transcriptionally more active than the primary P0 and P1 thyrocyte cultures, as the thyroid
499 markers analysed, *IYD*, *TG*, *TSHR*, *TPO*, *NIS*, were significantly higher in 3D conditions,
500 suggesting that recapitulating and preserving the original spatial organization of the primary
501 cells might impact different components of thyroid hormone metabolic machinery. Moreover,
502 even though not significantly, a further supplementation of TSH in the h7H culture medium
503 led to an increase in the transcript levels of the same thyroid markers, after 4 days of incubation
504 with the pituitary hormone, in comparison to the TSH starvation condition. This trend may also
505 be supported by change in TG production that shows an increase, yet not significantly, after 4-
506 day TSH incubation. This non-significance could be due to the organoid formation protocol or
507 to the strong dilution of metabolites released by organoid into the culture medium, because of
508 reduced size of the single organoid in each well compared to the volume of the medium, and
509 lastly to the presence of exogenous TG and THs in commercial sera which might hide small
510 differences in concentrations of released metabolites.

511 In fact, unlike Deisenroth (Deisenroth et al., 2020), our workflow brought to the formation of
512 a single organoid per well, starting with a smaller number of thyrocyte cells, and did not include
513 the use of any Matrigel matrix at the base of the well except for the little percentage, added to
514 the media, used to guarantee the stability of the 3D conformation. TG production in the two *in*
515 *vitro* model assays proved to be significantly greater in the 3D culture systems than in the 2D
516 ones. This evidence furtherly supports the results of TEM acquisition as well as thyroid marker
517 gene expression. Indeed, qRT-PCR revealed high transcription levels of *TG*, along with the
518 other highly expressed thyroid markers, pointing out how organoids potentially possess a
519 remarkably active metabolism.

520 Among the possible thyroid study-related applications, our 3D cultures were developed also
521 with the aim of creating a suitable model to investigate thyroid disorders induced by external
522 threats, in particular EDs, exposure to which may account for the increased incidence of
523 neurodevelopmental disorders and the average reduction in intelligence quotient witnessed in
524 recent decades (Colborn, 2004; Özel and Rüegg, 2023). Therefore, the formation of organoids
525 has been mainly focused on the impact of exogenous compounds, which exert competitive
526 inhibition of IYD, causing the disruption of iodide recycling, which instead is lost in the form
527 of MIT/DIT in urine and plasma (González-Guerrero et al., 2023; Shareef et al., 2023), thus
528 simulating an iodine deficiency situation (Jugan et al., 2010). Hence, to pursue this goal, we
529 followed the expression in our experimental models and then the activity of IYD in presence
530 3-MNT, that is a product of oxidative stress and a well-known IYD competitive inhibitor
531 (Green, 1968; Olker et al., 2021). Furthermore, since IYD belongs to the NADH-dependent
532 oxidoreductase superfamily, it is plausible that its inhibition would lead to an alteration of the
533 cellular redox and metabolic state. To evaluate the interfering action of the competitor 3-MNT
534 on the deiodination activity of IYD, we first assessed changes in the concentrations of MIT and
535 DIT in organoids' medium upon increasing doses of 3-MNT. Under physiological conditions,

536 the release of MIT and DIT is usually limited since these two metabolites, substrates of IYD,
537 are catabolized by the thyrocytes to recover the iodine necessary to produce subsequent
538 molecules of T3 and T4 (Czarnocka, 2013). However, when the action of IYD is inhibited or
539 hindered by the presence of interfering molecules, like 3-MNT, which competes with the
540 substrates of the enzyme, the release of MIT and DIT should significantly increase (González-
541 Guerrero et al., 2023). As matter of the fact, in our 3D culture at the highest concentration
542 tested, 3-MNT significantly increased MIT and DIT levels in the media, confirming the role of
543 3-MNT in inhibiting the recycling of iodine from TH precursor by IYD. These results candidate
544 our organoid model to be a convenient tool for investigating the interfering effects of some
545 xenobiotic molecules (at least members of the same class) on the thyroid system and into the
546 recycling system of iodine. Since 100 μ M 3-MNT was the unique effective treatment, further
547 investigations were performed only with the administration of this concentration. qRT-PCR
548 analysis showed that incubation with 3-MNT led to a significant increase in *IYD* and *TG*
549 expression levels, whilst *TSHR*, *NIS* and *TPO* were significantly decreased. Both *IYD* and *TG*
550 enhanced expressions could be explained as a compensatory mechanism in reaction to the
551 enzyme inhibition, thus, reduction of iodine recycling process as already described by Sun et
552 al. 2015 (Alikhani et al, 2023; Sun et al., 2015). TG production was significantly upregulated
553 by 4- day incubation with 100 μ M 3-MNT. This result could be seen as a compensatory
554 mechanism as well, following the dysfunction in the iodine recycling mechanism.

555 Our 3D model presents some limitations. First, primary thyrocytes from human samples are
556 short-lived, usually little available and can reflect the wide variability of patients (Toda et al.,
557 2011). Primary thyrocytes pose challenges in maintaining consistent cultures over extended
558 periods. Then, the variability among samples can potentially affect the reproducibility of
559 experimental outcomes. For this reason, immortalized thyroid-derived cell lines, that maintain
560 responsiveness to TSH and are still actively producing TG, could be seen as a successful step
561 to improve this experimental model (Hopperstad et al., 2021). This approach may enhance
562 model stability and reproducibility, offering a more standardized system for metabolic studies
563 and assessments of endocrine disruptors. Additionally, exploring time- and dose-dependent
564 response of endocrine disruptors beyond 3-MNT would deepen our understanding of this
565 model utility and its potential applications in toxicology and drug development. For instance,
566 a longer exposition may be performed to assess whether lower concentrations of 3-MNT may
567 impact on IYD activity. However, we must consider the lifespan of our organoids: we
568 performed all our assessments on 8–12-day organoids which, as verified by our measurements,
569 preserve their morphology and markers' expression. All these evaluations should be repeated
570 in organoids cultured for a longer age.

571 **Conclusions**

572 In this study we characterized and developed an organoid model of human thyroid that
573 morphologically and functionally conserves the identity of the gland; thus, it could represent
574 an alternative system to investigate thyroid metabolism and physiology, reducing, ultimately,
575 the application of animal models. Finally, due to its sensitivity to 3-MNT treatment leading to
576 IYD inhibition, an event that can also be caused by some EDs, this organoid model could be
577 considered a suitable tool to mimic and analyse the effects EDs on thyroid metabolism.

578

579 Acknowledgements

580 The authors thank Dr. Corinne Dupuy, from Genome Integrity and Cancers, UMR 8200/9019
581 CNRS, Paris-Saclay University, Gustave Roussy, Villejuif, France for providing stably
582 transfected DEHAL1 HEK293 cell line. The Centre for Instrumentation Sharing of University
583 of Pisa (CISUP) is kindly acknowledged for providing the Sciex QTrap 6500+ mass
584 spectrometer used for the mass spectrometric assays.

586 Data availability statement

587
588 The original contributions presented in the study are included in the article. Further inquiries
589 can be directed to the corresponding authors.

591 Conflicts of interest

592 The authors have no relevant financial or non-financial interests to disclose.

593 Authors contributions

594 Sofia Cristiani (SC), Andrea Bertolini (AB), Vittoria Carnicelli (VC), Lucia Contu (LC),
595 Valentina Vitelli (VV), Sandra Ghelardoni (SG), Grazia Chiellini (GC), Paola Lenzi (PL),
596 Maria Anita Giambelluca (MAG), Leonardo Rossi (LR), Grazia Rutigliano (GR):
597 Conceptualization, Methodology, Project administration, Validation, Data curation,
598 Visualization, Writing-original draft, Writing-review and editing. Alessandro Saba (AS),
599 Federica Saponaro (FS), Antonietta Raffaella Maria Sabbatini (ARMS), Francesco Fornai
600 (FF), Gabriele Materazzi (GM), Carlo Enrico Ambrosini (CEA), Ranieri Bizzarri (RB),
601 Riccardo Zucchi (RZ): review and editing.

603 Funding

604 This work was supported by a grant from University of Pisa to GR, RB, SG, GC, ARMS, PL,
605 FS, VC (PRA PRA_2020_77).

609 References

- 610 Alikhani P., González Guerrero C., Bertolini A., Vitelli V., Borsò M., Regojo R. M., Peluso
611 T., Salas-Lucia F., de la Vieja A., Saba A., Zucchi R., M.J.C., 2023. Dehal1 Deficiency
612 disrupts Thyroglobulin homeostasis and Impairs Iodine Storage. 45th Annu. Meet. Eur.
613 Thyroid Assoc.
- 614 Ameziane-El-Hassani, R., Morand, S., Boucher, J.-L., Frapart, Y.-M., Apostolou, D.,
615 Agnandji, D., Gnidehou, S., Ohayon, R., Noël-Hudson, M.-S., Francon, J., Lalaoui, K.,
616 Virion, A., Dupuy, C., 2005. Dual oxidase-2 has an intrinsic Ca²⁺-dependent H₂O₂-
617 generating activity. *J. Biol. Chem.* 280, 30046–30054.
618 <https://doi.org/10.1074/jbc.M500516200>

- 619 Antonica, F., Kasprzyk, D.F., Opitz, R., Iacovino, M., Liao, X.-H., Dumitrescu, A.M.,
620 Refetoff, S., Peremans, K., Manto, M., Kyba, M., Costagliola, S., 2012. Generation of
621 functional thyroid from embryonic stem cells. *Nature* 491, 66–71.
622 <https://doi.org/10.1038/nature11525>
- 623 Arvan, P., Kim, P.S., Kuliawat, R., Prabakaran, D., Muresan, Z., Yoo, S.E.U.N., Hossain,
624 S.A.B.U., 1997. Intracellular Protein Transport to the Thyrocyte Plasma Membrane:
625 Potential Implications for Thyroid Physiology. *Thyroid*® 7, 89–105.
626 <https://doi.org/10.1089/thy.1997.7.89>
- 627 Asawasinsopon, R., Prapamontol, T., Prakobvitayakit, O., Vaneesorn, Y., Mangklabruks, A.,
628 Hock, B., 2006. The association between organochlorine and thyroid hormone levels in
629 cord serum: a study from northern Thailand. *Environ. Int.* 32, 554–559.
630 <https://doi.org/10.1016/j.envint.2006.01.001>
- 631 Bandini, L., Sacripanti, G., Borsò, M., Tartaria, M., Fogliaro, M.P., Giannini, G., Carnicelli,
632 V., Figuccia, M.E., Verlotta, S., De Antoni, F., Zucchi, R., Ghelardoni, S., 2022.
633 Exogenous 3-Iodothyronamine (T(1)AM) Can Affect Phosphorylation of Proteins
634 Involved on Signal Transduction Pathways in In Vitro Models of Brain Cell Lines, but
635 These Effects Are Not Strengthened by Its Catabolite, 3-Iodothyroacetic Acid (TA(1)).
636 *Life* (Basel, Switzerland) 12. <https://doi.org/10.3390/life12091352>
- 637 Belforte, F.S., Targovnik, A.M., González-Lebrero, R.M., Osorio Larroche, C., Citterio, C.E.,
638 González-Sarmiento, R., Miranda, M. V, Targovnik, H.M., Rivolta, C.M., 2015. Kinetic
639 characterization of human thyroperoxidase. Normal and pathological enzyme
640 expression in Baculovirus system: a molecular model of functional expression. *Mol.*
641 *Cell. Endocrinol.* 404, 9–15. <https://doi.org/10.1016/j.mce.2014.12.026>
- 642 Bianco, A.C., Kim, B.W., 2006. Deiodinases: implications of the local control of thyroid
643 hormone action. *J. Clin. Invest.* 116, 2571–2579. <https://doi.org/10.1172/JCI29812>
- 644 Borsò, M., Agretti, P., Zucchi, R., Saba, A., 2022. Mass spectrometry in the diagnosis of
645 thyroid disease and in the study of thyroid hormone metabolism. *Mass Spectrom. Rev.*
646 41, 443–468. <https://doi.org/10.1002/mas.21673>
- 647 Bravo, S.B., Garcia-Rendueles, M.E.R., Garcia-Rendueles, A.R., Rodrigues, J.S., Perez-
648 Romero, S., Garcia-Lavandeira, M., Suarez-Fariña, M., Barreiro, F., Czarnocka, B.,
649 Senra, A., Lareu, M. V, Rodriguez-Garcia, J., Cameselle-Teijeiro, J., Alvarez, C. V,
650 2013. Humanized medium (h7H) allows long-term primary follicular thyroid cultures
651 from human normal thyroid, benign neoplasm, and cancer. *J. Clin. Endocrinol. Metab.*
652 98, 2431–2441. <https://doi.org/10.1210/jc.2012-3812>
- 653 Carvalho, D.P., Dupuy, C., 2013. Role of the NADPH Oxidases DUOX and NOX4 in
654 Thyroid Oxidative Stress. *Eur. Thyroid J.* 2, 160–167.
655 <https://doi.org/10.1159/000354745>
- 656 Chevrier, J., Eskenazi, B., Holland, N., Bradman, A., Barr, D.B., 2008. Effects of exposure to
657 polychlorinated biphenyls and organochlorine pesticides on thyroid function during
658 pregnancy. *Am. J. Epidemiol.* 168, 298–310. <https://doi.org/10.1093/aje/kwn136>
- 659 Citterio, C.E., Targovnik, H.M., Arvan, P., 2019. The role of thyroglobulin in thyroid
660 hormonogenesis. *Nat. Rev. Endocrinol.* 15, 323–338. <https://doi.org/10.1038/s41574-019-0184-8>
- 662 Colborn, T., 2004. Neurodevelopment and endocrine disruption. *Environ. Health Perspect.*

- 663 112, 944–949. <https://doi.org/10.1289/ehp.6601>
- 664 Czarnocka, B., 2013. The proteins of iodine metabolism in the pathophysiology of the thyroid
665 gland. *Thyroid Res.* <https://doi.org/10.1186/1756-6614-6-S2-A13>
- 666 Dalir Abdolahinia, E., Han, X., 2023. The Three-Dimensional In Vitro Cell Culture Models
667 in the Study of Oral Cancer Immune Microenvironment. *Cancers (Basel)*. 15.
668 <https://doi.org/10.3390/cancers15174266>
- 669 de Escobar, G.M., Obregón, M.J., del Rey, F.E., 2007. Iodine deficiency and brain
670 development in the first half of pregnancy. *Public Health Nutr.* 10, 1554–1570.
671 <https://doi.org/10.1017/S1368980007360928>
- 672 Deisenroth, C., Soldatow, V.Y., Ford, J., Stewart, W., Brinkman, C., LeCluyse, E.L.,
673 MacMillan, D.K., Thomas, R.S., 2020. Development of an In Vitro Human Thyroid
674 Microtissue Model for Chemical Screening. *Toxicol. Sci.* 174, 63–78.
675 <https://doi.org/10.1093/toxsci/kfz238>
- 676 Edmondson, R., Broglie, J.J., Adcock, A.F., Yang, L., 2014. Three-dimensional cell culture
677 systems and their applications in drug discovery and cell-based biosensors. *Assay Drug*
678 *Dev. Technol.* 12, 207–218. <https://doi.org/10.1089/adt.2014.573>
- 679 Estrada, J.M., Soldin, D., Buckey, T.M., Burman, K.D., Soldin, O.P., 2014. Thyrotropin
680 isoforms: implications for thyrotropin analysis and clinical practice. *Thyroid* 24, 411–
681 423. <https://doi.org/10.1089/thy.2013.0119>
- 682 Fabbro, D., Di Loreto, C., Beltrami, C.A., Belfiore, A., Di Lauro, R., Damante, G., 1994.
683 Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid
684 neoplasms. *Cancer Res.* 54, 4744–4749.
- 685 Fekete, C., Lechan, R.M., 2014. Central regulation of hypothalamic-pituitary-thyroid axis
686 under physiological and pathophysiological conditions. *Endocr. Rev.* 35, 159–194.
687 <https://doi.org/10.1210/er.2013-1087>
- 688 Fernández-Santos, J.M., Utrilla, J.C., Vázquez-Román, V., Villar-Rodríguez, J.L., Gutiérrez-
689 Avilés, L., Martín-Lacave, I., 2019. Primary Cilium in the Human Thyrocyte: Changes
690 in Frequency and Length in Relation to the Functional Pathology of the Thyroid Gland.
691 *Thyroid* 29, 595–606. <https://doi.org/10.1089/thy.2018.0401>
- 692 Fujita, H., 1975. Fine structure of the thyroid gland. *Int. Rev. Cytol.* 40, 197–280.
693 [https://doi.org/10.1016/s0074-7696\(08\)60954-7](https://doi.org/10.1016/s0074-7696(08)60954-7)
- 694 Gereben, B., McAninch, E.A., Ribeiro, M.O., Bianco, A.C., 2015. Scope and limitations of
695 iodothyronine deiodinases in hypothyroidism. *Nat. Rev. Endocrinol.* 11, 642–652.
696 <https://doi.org/10.1038/nrendo.2015.155>
- 697 Gillam, M.P., Sidhaye, A.R., Lee, E.J., Rutishauser, J., Stephan, C.W., Kopp, P., 2004.
698 Functional characterization of pendrin in a polarized cell system. Evidence for pendrin-
699 mediated apical iodide efflux. *J. Biol. Chem.* 279, 13004–13010.
700 <https://doi.org/10.1074/jbc.M313648200>
- 701 Gnidehou, S., Caillou, B., Talbot, M., Ohayon, R., Kaniewski, J., Noël-Hudson, M.-S.,
702 Morand, S., Agnangji, D., Sezan, A., Courtin, F., Virion, A., Dupuy, C., 2004.
703 Iodotyrosine dehalogenase 1 (DEHAL1) is a transmembrane protein involved in the
704 recycling of iodide close to the thyroglobulin iodination site. *FASEB J. Off. Publ. Fed.*
705 *Am. Soc. Exp. Biol.* 18, 1574–1576. <https://doi.org/10.1096/fj.04-2023fje>

- 706 Godlewska, M., Góra, M., Buckle, A.M., Porebski, B.T., Kemp, E.H., Sutton, B.J.,
707 Czarnocka, B., Banga, J.P., 2014. A redundant role of human thyroid peroxidase
708 propeptide for cellular, enzymatic, and immunological activity. *Thyroid* 24, 371–382.
709 <https://doi.org/10.1089/thy.2013.0127>
- 710 González-Guerrero, C., Borsò, M., Alikhani, P., Alcaina, Y., Salas-Lucia, F., Liao, X.-H.,
711 García-Giménez, J., Bertolini, A., Martin, D., Moratilla, A., Mora, R., Buño-Soto, A.,
712 Mani, A.R., Bernal, J., Saba, A., de Miguel, M.P., Refetoff, S., Zucchi, R., Moreno, J.C.,
713 2023. Iodotyrosines Are Biomarkers for Preclinical Stages of Iodine-Deficient
714 Hypothyroidism in Dehal1-Knockout Mice. *Thyroid* 33, 752–761.
715 <https://doi.org/10.1089/thy.2022.0537>
- 716 Green, W.L., 1968. Inhibition of thyroidal iodotyrosine deiodination by tyrosine analogues.
717 *Endocrinology* 83, 336–347. <https://doi.org/10.1210/endo-83-2-336>
- 718 Haddow, J.E., Palomaki, G.E., Allan, W.C., Williams, J.R., Knight, G.J., Gagnon, J., O’Heir,
719 C.E., Mitchell, M.L., Hermos, R.J., Waisbren, S.E., Faix, J.D., Klein, R.Z., 1999.
720 Maternal thyroid deficiency during pregnancy and subsequent neuropsychological
721 development of the child. *N. Engl. J. Med.* 341, 549–555.
722 <https://doi.org/10.1056/NEJM199908193410801>
- 723 Hetzel, B.S., 2000. Iodine and neuropsychological development. *J. Nutr.* 130, 493S-495S.
724 <https://doi.org/10.1093/jn/130.2.493S>
- 725 Hopperstad, K., Truschel, T., Wahlicht, T., Stewart, W., Eicher, A., May, T., Deisenroth, C.,
726 2021. Characterization of Novel Human Immortalized Thyroid Follicular Epithelial Cell
727 Lines. *Appl. Vitro. Toxicol.* 7, 39–49. <https://doi.org/10.1089/aivt.2020.0027>
- 728 Hwang, D.G., Choi, Y.-M., Jang, J., 2021. 3D Bioprinting-Based Vascularized Tissue
729 Models Mimicking Tissue-Specific Architecture and Pathophysiology for in vitro
730 Studies. *Front. Bioeng. Biotechnol.* 9, 685507.
731 <https://doi.org/10.3389/fbioe.2021.685507>
- 732 Jubelin, C., Muñoz-García, J., Griscom, L., Cochonneau, D., Ollivier, E., Heymann, M.-F.,
733 Vallette, F.M., Oliver, L., Heymann, D., 2022. Three-dimensional in vitro culture
734 models in oncology research. *Cell Biosci.* 12, 155. <https://doi.org/10.1186/s13578-022-00887-3>
- 736 Jugan, M.-L., Levi, Y., Blondeau, J.-P., 2010. Endocrine disruptors and thyroid hormone
737 physiology. *Biochem. Pharmacol.* 79, 939–947.
738 <https://doi.org/10.1016/j.bcp.2009.11.006>
- 739 Kogai, T., Endo, T., Saito, T., Miyazaki, A., Kawaguchi, A., Onaya, T., 1997. Regulation by
740 thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein
741 levels in FRTL-5 cells. *Endocrinology* 138, 2227–2232.
742 <https://doi.org/10.1210/endo.138.6.5189>
- 743 Kurmann, A.A., Serra, M., Hawkins, F., Rankin, S.A., Mori, M., Astapova, I., Ullas, S., Lin,
744 S., Bilodeau, M., Rossant, J., Jean, J.C., Ikonomou, L., Deterding, R.R., Shannon, J.M.,
745 Zorn, A.M., Hollenberg, A.N., Kotton, D.N., 2015. Regeneration of Thyroid Function
746 by Transplantation of Differentiated Pluripotent Stem Cells. *Cell Stem Cell* 17, 527–
747 542. <https://doi.org/10.1016/j.stem.2015.09.004>
- 748 Lelièvre, S.A., Kwok, T., Chittiboyina, S., 2017. Architecture in 3D cell culture: An essential
749 feature for in vitro toxicology. *Toxicol. Vitro. an Int. J. Publ. Assoc. with BIBRA* 45,

- 750 287–295. <https://doi.org/10.1016/j.tiv.2017.03.012>
- 751 Liang, J., Li, X., Dong, Y., Zhao, B., 2022. Modeling Human Organ Development and
752 Diseases With Fetal Tissue-Derived Organoids. *Cell Transplant.* 31,
753 9636897221124480. <https://doi.org/10.1177/09636897221124481>
- 754 Livak, K.J., Schmittgen, T.D., 2001. Analysis of relative gene expression data using real-time
755 quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25, 402–408.
756 <https://doi.org/10.1006/meth.2001.1262>
- 757 Longmire, T.A., Ikonomidou, L., Hawkins, F., Christodoulou, C., Cao, Y., Jean, J.C., Kwok,
758 L.W., Mou, H., Rajagopal, J., Shen, S.S., Dowton, A.A., Serra, M., Weiss, D.J., Green,
759 M.D., Snoeck, H.-W., Ramirez, M.I., Kotton, D.N., 2012. Efficient derivation of
760 purified lung and thyroid progenitors from embryonic stem cells. *Cell Stem Cell* 10,
761 398–411. <https://doi.org/10.1016/j.stem.2012.01.019>
- 762 Lopez-Espinosa, M.-J., Vizcaino, E., Murcia, M., Llop, S., Espada, M., Seco, V., Marco, A.,
763 Rebagliato, M., Grimalt, J.O., Ballester, F., 2009. Association between thyroid hormone
764 levels and 4,4'-DDE concentrations in pregnant women (Valencia, Spain). *Environ.*
765 *Res.* 109, 479–485. <https://doi.org/10.1016/j.envres.2009.02.003>
- 766 Luongo, C., Dentice, M., Salvatore, D., 2019. Deiodinases and their intricate role in thyroid
767 hormone homeostasis. *Nat. Rev. Endocrinol.* 15, 479–488.
768 <https://doi.org/10.1038/s41574-019-0218-2>
- 769 Matuszewski, B.K., Constanzer, M.L., Chavez-Eng, C.M., 2003. Strategies for the
770 assessment of matrix effect in quantitative bioanalytical methods based on HPLC-
771 MS/MS. *Anal. Chem.* 75, 3019–3030. <https://doi.org/10.1021/ac020361s>
- 772 Ohno, M., Zannini, M., Levy, O., Carrasco, N., di Lauro, R., 1999. The paired-domain
773 transcription factor Pax8 binds to the upstream enhancer of the rat sodium/iodide
774 symporter gene and participates in both thyroid-specific and cyclic-AMP-dependent
775 transcription. *Mol. Cell. Biol.* 19, 2051–2060. <https://doi.org/10.1128/MCB.19.3.2051>
- 776 Olker, J.H., Haselman, J.T., Kosian, P.A., Donnay, K.G., Korte, J.J., Blanksma, C., Hornung,
777 M.W., Degitz, S.J., 2018. Evaluating Iodide Recycling Inhibition as a Novel Molecular
778 Initiating Event for Thyroid Axis Disruption in Amphibians. *Toxicol. Sci.* 166, 318–
779 331. <https://doi.org/10.1093/toxsci/kfy203>
- 780 Olker, J.H., Korte, J.J., Denny, J.S., Haselman, J.T., Hartig, P.C., Cardon, M.C., Hornung,
781 M.W., Degitz, S.J., 2021. In vitro screening for chemical inhibition of the iodide
782 recycling enzyme, iodotyrosine deiodinase. *Toxicol. Vitro. an Int. J. Publ. Assoc. with*
783 *BIBRA* 71, 105073. <https://doi.org/10.1016/j.tiv.2020.105073>
- 784 Özel, F., Rüegg, J., 2023. Exposure to endocrine-disrupting chemicals and implications for
785 neurodevelopment. *Dev. Med. Child Neurol.* 65, 1005–1011.
786 <https://doi.org/10.1111/dmcn.15551>
- 787 Portulano, C., Paroder-Belenitsky, M., Carrasco, N., 2014. The Na⁺/I⁻ symporter (NIS):
788 mechanism and medical impact. *Endocr. Rev.* 35, 106–149.
789 <https://doi.org/10.1210/er.2012-1036>
- 790 Román, G.C., Ghassabian, A., Bongers-Schokking, J.J., Jaddoe, V.W. V, Hofman, A., de
791 Rijke, Y.B., Verhulst, F.C., Tiemeier, H., 2013. Association of gestational maternal
792 hypothyroxinemia and increased autism risk. *Ann. Neurol.* 74, 733–742.

- 793 <https://doi.org/10.1002/ana.23976>
- 794 Romitti, M., Tourneur, A., de Faria da Fonseca, B., Doumont, G., Gillotay, P., Liao, X.-H.,
795 Eski, S.E., Van Simaey, G., Chomette, L., Lasolle, H., Monestier, O., Kasprzyk, D.F.,
796 Detours, V., Singh, S.P., Goldman, S., Refetoff, S., Costagliola, S., 2022. Transplantable
797 human thyroid organoids generated from embryonic stem cells to rescue
798 hypothyroidism. *Nat. Commun.* 13, 7057. <https://doi.org/10.1038/s41467-022-34776-7>
- 799 Samimi, H., Atlasi, R., Parichehreh-Dizaji, S., Khazaei, S., Akhavan Rahnama, M., Seifirad,
800 S., Haghpanah, V., 2021. A systematic review on thyroid organoid models: time-trend
801 and its achievements. *Am. J. Physiol. Endocrinol. Metab.* 320, E581–E590.
802 <https://doi.org/10.1152/ajpendo.00479.2020>
- 803 Sewell, W., Lin, R.-Y., 2014. Generation of thyroid follicular cells from pluripotent stem
804 cells: potential for regenerative medicine. *Front. Endocrinol. (Lausanne)*. 5, 96.
805 <https://doi.org/10.3389/fendo.2014.00096>
- 806 Shankaran, A., Prasad, K., Chaudhari, S., Brand, A., Satyamoorthy, K., 2021. Advances in
807 development and application of human organoids. *3 Biotech* 11, 257.
808 <https://doi.org/10.1007/s13205-021-02815-7>
- 809 Shareef, R., Furman, A., Watanabe, Y., Bruellman, R., Abdullah, M.A., Dumitresu, A.M.,
810 Refetoff, S., Bertolini, A., Borsò, M., Saba, A., Zucchi, R., Weiss, R.E., 2023.
811 Congenital Hypothyroidism in Two Sudanese Families Harboring a Novel Iodotyrosine
812 Deiodinase Mutation (IYD R279C). *Thyroid* 33, 261–266.
813 <https://doi.org/10.1089/thy.2022.0492>
- 814 Shiloh, H., Iancu, T.C., Sheinfeld, M., Kraiem, Z., 1987. The influence of cryopreservation
815 on the ultrastructural morphology of human thyroid cells. *Cryobiology* 24, 303–310.
816 [https://doi.org/10.1016/0011-2240\(87\)90034-4](https://doi.org/10.1016/0011-2240(87)90034-4)
- 817 Sun, X., Zhang, X., Jiang, Y., Bao, S., Shan, Z., Teng, W., 2015. Expression of Iodotyrosine
818 Deiodinase in Thyroid and Other Organs in Iodine-Deficient and Iodine-Excess Rats.
819 *Biol. Trace Elem. Res.* 167, 272–279. <https://doi.org/10.1007/s12011-015-0328-1>
- 820 Tannenbaum, J., Bennett, B.T., 2015. Russell and Burch's 3Rs then and now: the need for
821 clarity in definition and purpose. *J. Am. Assoc. Lab. Anim. Sci.* 54, 120–132.
- 822 Toda, S., Aoki, S., Uchihashi, K., Matsunobu, A., Yamamoto, M., Ootani, A., Yamasaki, F.,
823 Koike, E., Sugihara, H., 2011. Culture Models for Studying Thyroid Biology and
824 Disorders. *ISRN Endocrinol.* 2011, 275782. <https://doi.org/10.5402/2011/275782>
- 825 Utrilla, J.C., Gordillo-Martínez, F., Gómez-Pascual, A., Fernández-Santos, J.M., Garnacho,
826 C., Vázquez-Román, V., Morillo-Bernal, J., García-Marín, R., Jiménez-García, A.,
827 Martín-Lacave, I., 2015. Comparative study of the primary cilia in thyrocytes of adult
828 mammals. *J. Anat.* 227, 550–560. <https://doi.org/10.1111/joa.12360>
- 829 van der Vaart, J., Bosmans, L., Sijbesma, S.F., Knoops, K., van de Wetering, W.J., Otten,
830 H.G., Begthel, H., Borel Rinkes, I.H.M., Korving, J., Lentjes, E.G.W.M., Lopez-
831 Iglesias, C., Peters, P.J., van Santen, H.M., Vriens, M.R., Clevers, H., 2021. Adult
832 mouse and human organoids derived from thyroid follicular cells and modeling of
833 Graves' hyperthyroidism. *Proc. Natl. Acad. Sci. U. S. A.* 118.
834 <https://doi.org/10.1073/pnas.2117017118>
- 835 Wang, Y., Li, W., Phay, J.E., Shen, R., Pellegata, N.S., Saji, M., Ringel, M.D., de la

- 836 Chapelle, A., He, H., 2016. Primary Cell Culture Systems for Human Thyroid Studies.
837 Thyroid 26, 1131–1140. <https://doi.org/10.1089/thy.2015.0518>
- 838 Wheatley, D.N., 2018. The primary cilium - once a “rudimentary” organelle that is now a
839 ubiquitous sensory cellular structure involved in many pathological disorders. J. Cell
840 Commun. Signal. 12, 211–216. <https://doi.org/10.1007/s12079-017-0436-0>
- 841 Wheatley, D.N., 2010. Another decade of advances in research on primary cilia, porosomes
842 and neosis: some passing thoughts at 70. Cell Biol. Int.
843 <https://doi.org/10.1042/CBI20100119>
- 844 Wheatley, D.N., 2005. Landmarks in the first hundred years of primary (9+0) cilium
845 research. Cell Biol. Int. 29, 333–339. <https://doi.org/10.1016/j.cellbi.2005.03.001>
- 846 Wright, E.M., Turk, E., 2004. The sodium/glucose cotransport family SLC5. Pflugers Arch.
847 447, 510–518. <https://doi.org/10.1007/s00424-003-1063-6>
- 848 Yokoyama, N., Taurog, A., 1988. Porcine thyroid peroxidase: relationship between the native
849 enzyme and an active, highly purified tryptic fragment. Mol. Endocrinol. 2, 838–844.
850 <https://doi.org/10.1210/mend-2-9-838>
- 851 Zhang, Y., Fu, M., Wang, H., Sun, H., 2023. Advances in the Construction and Application
852 of Thyroid Organoids. Physiol. Res. 72, 557–564.
853 <https://doi.org/10.33549/physiolres.935102>
- 854 Zhao, Z., Chen, X., Dowbaj, A.M., Sljukic, A., Bratlie, K., Lin, L., Fong, E.L.S.,
855 Balachander, G.M., Chen, Z., Soragni, A., Huch, M., Zeng, Y.A., Wang, Q., Yu, H.,
856 2022. Organoids. Nat. Rev. Methods Prim. 2. <https://doi.org/10.1038/s43586-022-00174-y>
- 857
- 858 Zimmermann, M.B., Jooste, P.L., Pandav, C.S., 2008. Iodine-deficiency disorders. Lancet
859 (London, England) 372, 1251–1262. [https://doi.org/10.1016/S0140-6736\(08\)61005-3](https://doi.org/10.1016/S0140-6736(08)61005-3)

860

861

862

863 **Figure captions**

864 **Figure 1. Thyroid organoid formation and immunofluorescence characterization.** A)
865 Brightfield images depicting digested primary thyrocytes and 2D thyrocytes at confluence (A1-
866 2). Organoid formation: once thyrocytes reached confluence, they were seeded in Nunclon
867 Sphera™ microplates to form organoid that could be seen in the following 24 hours (A3);
868 organoid after 7 days (A4); after 10 days from formation (A5); 3D cultures were then collected
869 for characterization analyses. Scale bar: 100 μm. B) Confocal images of 2D P0 primary
870 thyrocytes expressing TSHR (magenta A3), TTF-1 (red B3), IYD (green A2), and α-Tubulin
871 (cyan B2). Nuclei are stained with DAPI. Scale bar: 25 μm (B); 10 μm (A). C) Confocal images
872 of 3D cultures (A; B; C; D) expressing TSHR (magenta A3), TTF-1 (red B3), IYD (green C2),
873 and Phalloidin (white A2). The same organoids in D1 are also shown in brightfield microscopy
874 in D2. Nuclei are stained with DAPI. Scale bar: 100 μm (A; C); 25 μm (B).

875

876 **Figure 2. Light microscopy and transmission electron microscopy characterization.** A)
 877 Representative pictures at light microscopy and transmission electron microscopy (TEM) from
 878 a human non-tumorous thyroid organoid. A1, Toluidine blue histochemistry was carried out on
 879 semi-thin slices (1 μm -thick) in which an organoid shown the inner cavity (*), well evident at
 880 ultrastructural level (A2). In the cell apical surface microvilli protrude within the cavity (A3,
 881 arrows). In sub-apical cytoplasm droplets are evident (A4, arrows) Scale bar: A1= 12.5 μm ;
 882 A2= 0.6 μm ; A3= 300 nm; A4= 2.5 μm . B) TEM representative picture of organoid epithelial
 883 cell: B1 cell junctions (arrows), B2 dilated cisternae of RER, B3 Golgi apparatus and small
 884 vesicles (V), B4 numerous lysosome-like organelles. M=mitochondria, N=nucleus,
 885 L=Lysosome-like structure. PC=primary cilium. RER=rough endoplasmic reticulum. Scale
 886 bar: B1= 150 nm; B2= 0.23 μm ; B3= 300 nm; B4= 300 nm.

887
 888 **Figure 3. Expression of thyroid markers in 2D cells and organoids.** A) Gene expression:
 889 relative expressions of thyroid markers in primary thyrocytes at passages 0 (P0, reference
 890 sample), 1 (P1) and organoids (3D) by qRT-PCR. 2D (P0 and P1) and 3D culture sample data
 891 were normalized to internal reference control (*GAPDH*) and expressed as the relative
 892 expression (fold-change) to P0 thyrocytes. The results are expressed as mean \pm S.E.M.
 893 Statistical analysis was performed through one-way ANOVA and post hoc test Tukey, with a
 894 significant p value * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$; N= 3. B) Western blotting with IYD
 895 antibody in 2D cells, organoid lysates and thyroid extract. B1) Lysates of primary thyroid cells
 896 at passages 0 (P0), 1 (P1), and 2 (P2) and thyroid extract (C+): in lane P0 and C+, the band
 897 between 25 and 37 kDa is specific, being seen in presence of antibody anti IYD but not after
 898 incubation with blocking peptide (B2). This band disappears following incubation with
 899 blocking peptide, signifying the specificity of IYD. B3) α -actin (42 kDa) in 2D cell lysates and
 900 tissues extract (C+). B4) Lysates from cells at passage 0 (P0), from a pool of organoids cultured
 901 in Nunclon SphereTM (3D), from HEK293 cells transfected with IYD (DEHAL1) (C);
 902 immunoblotting with anti-IYD highlighted a band between 25 and 37 kDa in all lanes. B5) α -
 903 actin (42 kDa) in 2D cell lysate and organoids. Numbers are molecular weight (kDa); M,
 904 protein standards (Precision Plus ProteinTM KaleidoscopeTM Prestained Protein
 905 Standards #1610375 Biorad). C) TG ELISA assay in exhausted media of 2D, at P0 and P1, and
 906 3D cultures. The results are expressed as mean \pm S.E.M. Statistical analysis is performed
 907 through *t*-test, with a significant p value **** $p < 0.0001$; N= 3.

908

909 **Figure 4. Effects of TSH stimulation.** A) TG concentration in media by ELISA assay on 3D
 910 cultures with or without 2 mU/mL TSH incubation for 4 days. The results are expressed as
 911 mean \pm S.E.M. Statistical analysis was performed through *t*-test, P=NS; N= 3. B) Relative
 912 expressions of thyroid markers in 3D cultures after incubation with 2 mU/mL TSH (TSH), as
 913 opposed to no TSH further addition (no TSH), for 4 days, by qRT-PCR. The culture sample
 914 data were normalized to internal reference control (*GAPDH*) and expressed as the relative
 915 expression (fold-change) to no TSH. The results are expressed as mean \pm S.E.M. Statistical
 916 analysis was performed by *t*-test. P=NS; N= 3. C) Organoid TH production in media samples.
 917 The production rate of TH by organoids is expressed as ratio between the concentration of TH
 918 in the media recovered from the organoids wells after 4 days of treatment with an additional
 919 TSH external stimulus and TH in the blank media, without additional TSH stimulus.

920 Experiments were conducted in triplicate. Results are expressed as Mean \pm S.E.M. Statistical
921 analysis was performed by *t*-test. P=NS

922

923 **Figure 5. Effect of the IYD inhibitor 3-mononitrotyrosine (3-MNT) on thyroid function.**

924 A) MTT assay on monolayer primary thyrocytes to test cell viability after 24-hour incubation
925 with increasing concentrations of 3-MNT for 4 days. The results are expressed as mean \pm
926 S.E.M. of 4 technical replicates. B) Effect of 3-MNT inhibition on IYD enzyme. Differences
927 between groups are expressed as ratios between the treated groups (0.01-1-100 μ M 3-MNT)
928 and the control vehicle condition (NaOH). Experiments were all conducted in triplicate. Results
929 are expressed as Mean \pm S.E.M. Two-way ANOVA and Tukey's multiple comparison test
930 were performed to evaluate statistical differences between groups; * $p < 0.05$, **** $p < 0.001$ vs
931 control § $p < 0.001$ vs 0.01/1 μ M MNT treatment. C) TG ELISA assay on 3D culture after
932 incubation with 3-MNT 100 μ M for 4 days. The results are expressed as mean \pm S.E.M.
933 Statistical analysis was performed through *t*-test, with a significant *p* value ** $p < 0.01$; N= 3. D)
934 Relative expressions of thyroid markers in 3D cultures after incubation with 100 μ M 3-MNT
935 for 4 days, by qRT-PCR. Sample data from treatment condition (100 μ M 3-MNT) were
936 normalized to internal reference control (*GAPDH*) and expressed as the relative expression
937 (fold-change) vs control (0.05 mM NaOH). The results are expressed as mean \pm S.E.M.
938 Statistical analysis was performed by *t*-test, with a significant *p* value * $p < 0.05$, ** $p < 0.01$,
939 *** $p < 0.001$; N= 3.

940

Figure captions

Figure 1. Thyroid organoid formation and immunofluorescence characterization. A) Brightfield images depicting digested primary thyrocytes and 2D thyrocytes at confluence (A1-2). Organoid formation: once thyrocytes reached confluence, they were seeded in Nunclon Sphera™ microplates to form organoid that could be seen in the following 24 hours (A3); organoid after 7 days (A4); after 10 days from formation (A5); 3D cultures were then collected for characterization analyses. Scale bar: 100 μm . B) Confocal images of 2D P0 primary thyrocytes expressing TSHR (magenta A3), TTF-1 (red B3), IYD (green A2), and α -Tubulin (cyan B2). Nuclei are stained with DAPI. Scale bar: 25 μm (B); 10 μm (A). C) Confocal images of 3D cultures (A; B; C; D) expressing TSHR (magenta A3), TTF-1 (red B3), IYD (green C2), and Phalloidin (white A2). The same organoids in D1 are also shown in brightfield microscopy in D2. Nuclei are stained with DAPI. Scale bar: 100 μm (A; C); 25 μm (B).

Figure 2. Light microscopy and transmission electron microscopy characterization. A) Representative pictures at light microscopy and transmission electron microscopy (TEM) from a human non-tumorous thyroid organoid. A1, Toluidine blue histochemistry was carried out on semi-thin slices (1 μm -thick) in which an organoid shown the inner cavity (*), well evident at ultrastructural level (A2). In the cell apical surface microvilli protrude within the cavity (A3, arrows). In sub-apical cytoplasm droplets are evident (A4, arrows) Scale bar: A1= 12.5 μm ; A2= 0.6 μm ; A3= 300 nm; A4= 2.5 μm . B) TEM representative picture of organoid epithelial cell: B1 cell junctions (arrows), B2 dilated cisternae of RER, B3 Golgi apparatus and small vesicles (V), B4 numerous lysosome-like organelles. M=mitochondria, N=nucleus, L=Lysosome-like structure. PC=primary cilium. RER=rough endoplasmic reticulum. Scale bar: B1= 150 nm; B2= 0.23 μm ; B3= 300 nm; B4= 300 nm.




Figure 3. Expression of thyroid markers in 2D cells and organoids. A) Gene expression: relative expressions of thyroid markers in primary thyrocytes at passages 0 (P0, reference sample), 1 (P1) and organoids (3D) by qRT-PCR. 2D (P0 and P1) and 3D culture sample data were normalized to internal reference control (*GAPDH*) and expressed as the relative expression (fold-change) to P0 thyrocytes. The results are expressed as mean \pm S.E.M. Statistical analysis was performed through one-way ANOVA and post hoc test Tukey, with a significant p value * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$; N= 3. B) Western blotting with IYD antibody in 2D cells, organoid lysates and thyroid extract. B1) Lysates of primary thyroid cells at passages 0 (P0), 1 (P1), and 2 (P2) and thyroid extract (C+): in lane P0 and C+, the band between 25 and 37 kDa is specific, being seen in presence of antibody anti IYD but not after incubation with blocking peptide (B2). This band disappears following incubation with blocking peptide, signifying the specificity of IYD. B3) α -actin (42 kDa) in 2D cell lysates and tissues extract (C+). B4) Lysates from cells at passage 0 (P0), from a pool of organoids cultured in Nunclon Sphere™ (3D), from HEK293 cells transfected with IYD (DEHAL1) (C); immunoblotting with anti-IYD highlighted a band between 25 and 37 kDa in all lanes. B5) α -actin (42 kDa) in 2D cell lysate and organoids. Numbers are molecular weight (kDa); M, protein standards (Precision Plus Protein™ Kaleidoscope™ Prestained Protein Standards #1610375 Biorad). C) TG ELISA assay in exhausted media of 2D, at P0 and P1, and 3D cultures. The results are expressed as mean \pm S.E.M. Statistical analysis is performed through *t*-test, with a significant p value **** $p < 0.0001$; N= 3.

Figure 4. Effects of TSH stimulation. A) TG concentration in media by ELISA assay on 3D cultures with or without 2 mU/mL TSH incubation for 4 days. The results are expressed as mean \pm S.E.M. Statistical analysis was performed through *t*-test, P=NS; N= 3. B) Relative expressions of thyroid markers in 3D cultures after incubation with 2 mU/mL TSH (TSH), as opposed to no TSH further addition (no TSH), for 4 days, by qRT-PCR. The culture sample data were normalized to internal reference control (*GAPDH*) and expressed as the relative expression (fold-change) to no TSH. The results are expressed as mean \pm S.E.M. Statistical analysis was performed by *t*-test. P=NS; N= 3. C) Organoid TH production in media samples. The production rate of TH by organoids is expressed as ratio between the concentration of TH in the media recovered from the organoids wells after 4 days of treatment with an additional TSH external stimulus and TH in the blank media, without additional TSH stimulus. Experiments were conducted in triplicate. Results are expressed as Mean \pm S.E.M. Statistical analysis was performed by *t*-test. P=NS

Figure 5. Effect of the IYD inhibitor 3-mononitrotyrosine (3-MNT) on thyroid function. A) MTT assay on monolayer primary thyrocytes to test cell viability after 24-hour incubation with increasing concentrations of 3-MNT for 4 days. The results are expressed as mean \pm S.E.M. of 4 technical replicates. B) Effect of 3-MNT inhibition on IYD enzyme. Differences between groups are expressed as ratios between the treated groups (0.01-1-100 μ M 3-MNT) and the control vehicle condition (NaOH). Experiments were all conducted in triplicate. Results are expressed as Mean \pm S.E.M. Two-way ANOVA and Tukey's multiple comparison test were performed to evaluate statistical differences between groups; * $p < 0.05$, **** $p < 0.001$ vs control § $p < 0.001$ vs 0.01/1 μ M MNT treatment. C) TG ELISA assay on 3D culture after incubation with 3-MNT 100 μ M for 4 days. The results are expressed as mean \pm S.E.M. Statistical analysis was performed through *t*-test, with a significant *p* value ** $p < 0.01$; N= 3. D) Relative expressions of thyroid markers in 3D cultures after incubation with 100 μ M 3-MNT for 4 days, by qRT-PCR. Sample data from treatment condition (100 μ M 3-MNT) were normalized to internal reference control (*GAPDH*) and expressed as the relative expression (fold-change) vs control (0.05 mM NaOH). The results are expressed as mean \pm S.E.M. Statistical analysis was performed by *t*-test, with a significant *p* value * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$; N= 3.


Journal Pre-proof

Figure 1




Journal Pre-proof

Figure 2




Journal Pre-proof

Figure 3




Journal Pre-proof

Figure 4



Journal Pre-proof

Figure 5



Highlights

- Enhanced marker expression in 3D cultures reveals organoid model fidelity.
- 3D thyroid cultures are valuable for studying metabolism and disorders.
- Organoid-based thyroid model offers insight into endocrine disruptors.
- Thyroid organoids provide ethical research avenues for studying gland function.

Journal Pre-proof

Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Journal Pre-proof